A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Part of paid clinical trials in Daphne, Alabama.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT07361497
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pumitamig — DRUGSpecified dose on specified days
- Durvalumab — DRUGSpecified dose on specified days
Study Details
A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
Key Dates
- First listed
- Jan 23, 2026
- Start date
- Mar 16, 2026
- Status verified
- Jul 2026
- Primary completion
- Sep 18, 2030
- Completion
- Dec 31, 2033
Study Design
- Enrollment
- 850 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A
- Active Comparator: Arm B
Primary Outcome Measure
Progression-free survival (PFS) by blinded independent central review (BICR) (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1) [ Time Frame: Up to 3 years ]
Central Contacts
- BMS Clinical Trials Contact Center www.BMSClinicalTrials.com855-907-3286
- First line of the email MUST contain NCT # and Site #.
Locations (38)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Southern Cancer Center Pc | Daphne | Alabama | 36526 | Michael Meshad, Site 0898 111-111-1111 |
| Local Institution - 0780 | Chandler | Arizona | 85224 | Site 0780 |
| Intermountain Health Cancer Center Lutheran Hospital | Golden | Colorado | 80401 | Karng Log, Site 0585 303-403-7333 |
| Medical Oncology Hematology Consultants, PA | Newark | Delaware | 19713 | Jamal Misleh, Site 0896 302-366-1200 |
| Local Institution - 0711 | Ocala | Florida | 34474 | Site 0711 |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | Marietta | Georgia | 30060 | Walid Shaib, Site 0756 770-281-5124 |
| Local Institution - 0398 | Chicago | Illinois | 60637 | Site 0398 |
| Local Institution - 0850 | Evanston | Illinois | 60201 | Site 0850 |
| Illinois Cancer Care | Peoria | Illinois | 61615 | Srinivas Jujjavarapu, Site 0897 309-243-3000 |
| Fort Wayne Medical Oncology and Hematology | Fort Wayne | Indiana | 46804 | Ahad Sadiq, Site 0317 260-436-0800 |
| University of Kentucky Chandler Medical Center | Lexington | Kentucky | 40536 | Zhonglin Hao, Site 0656 859-218-6704 |
| Local Institution - 0603 | Boston | Massachusetts | 02114-2621 | Site 0603 |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | Khalil Choucair, Site 0419 |
| Minnesota Oncology Hematology | Maple Grove | Minnesota | 55369 | Daniel Mundt, Site 0322 |
| Local Institution - 0142 | Saint Paul | Minnesota | 55102 | Site 0142 |
| Missouri Cancer Associates | Columbia | Missouri | 65201 | Caleb Smith, Site 0900 |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Mark Awad, Site 0606 |
| Local Institution - 0339 | Westbury | New York | 11590 | - |
| Optum Medical Care, PC | Westbury | New York | 11590 | Jonathan Goldberg, Site 0909 914-242-2991 |
| Local Institution - 0493 | Winston-Salem | North Carolina | 27103 | Site 0493 |
| Local Institution - 0923 | Akron | Ohio | 44302 | Site 0923 |
| Local Institution - 0412 | Cincinnati | Ohio | 45219 | Site 0412 |
| Local Institution - 0359 | Cleveland | Ohio | 44106-5066 | Site 0359 |
| Local Institution - 0597 | Cleveland | Ohio | 44195 | Site 0597 |
| Local Institution - 0924 | Mayfield Heights | Ohio | 44124 | Site 0924 |
| Oncology Associates Of Oregon, Pc | Eugene | Oregon | 97401 | Bo Wang, Site 0895 541-683-5001 |
| Northwest Cancer Specialists, P.C. | Happy Valley | Oregon | 97015 | Anthony Van Ho, Site 0302 503-885-5411 |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Melissa Johnson, Site 0240 615-329-7274 |
| Tennessee Oncology | Nashville | Tennessee | 37203 | Wade Iams, Site 0480 615-322-4967 |
| Texas Oncology - Amarillo Cancer Center | Amarillo | Texas | 79124 | Pankaj Khandelwal, Site 0908 000-000-0000 |
| Texas Oncology-Austin Central | Austin | Texas | 78731 | James Uyeki, Site 0857 512-427-9400 |
| Texas Oncology | Denton | Texas | 76210 | Kartik Konduri, Site 0894 214-370-1000 |
| The Center For Cancer And Blood Disorders | Fort Worth | Texas | 76104 | Ray Page, Site 0811 817-759-7000 |
| The University of Texas-MD Anderson Cancer Center | Houston | Texas | 77030 | Tina Cascone, Site 0596 713-792-6363 |
| Texas Oncology - San Antonio Medical Center | San Antonio | Texas | 78229 | Krishna Alluri, Site 0902 210-656-7177 |
| Texas Oncology - Northeast Texas | Tyler | Texas | 75702 | Sarah Wang, Site 0899 903-579-9800 |
| Blue Ridge Cancer Care | Christiansburg | Virginia | 24073 | Jerome Goldschmidt, Site 0133 540-381-5291 |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | John Paschold, Site 0250 |
Find similar trials in Daphne, AL
By research site
Southern Cancer Center Pc· Daphne, ALLocal Institution - 0780· Chandler, AZIntermountain Health Cancer Center Lutheran Hospital· Golden, COMedical Oncology Hematology Consultants, PA· Newark, DELocal Institution - 0711· Ocala, FLNorthwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital· Marietta, GA
Related Studies
- ROSE for Improved Molecular Marker Testing Via EBUSEnrolling By Invitation · Johns Hopkins University · Chicago, Illinois
- A Study of NX-1607 in Adults With Advanced MalignanciesPHASE1 · Recruiting · Nurix Therapeutics, Inc. · Los Angeles, California
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPHASE1 · Recruiting · Exelixis · Phoenix, Arizona
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASPHASE1/PHASE2 · Recruiting · Revolution Medicines, Inc. · Orange, California